MA Chief Executive appointed to IFPMA
This week it was announced that Medicines Australia Chief Executive, Dr Brendan Shaw, will be appointed to a position as Assistant Director General at the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) in Geneva, Switzerland.
Dr Shaw will finish his tenure as Medicines Australia Chief Executive on 12 September and take up his new position at the IFPMA in Geneva in December.
Dr Shaw will have overview of global health policy for the IFPMA, reporting to the Director General and working on a range of issues including reimbursement, health technology assessment, access to medicines, vaccines and communications.
Medicines Australia Chairman, Dr Martin Cross, welcomed the announcement of Dr Shaw’s new role.
“This is a real credit to Brendan and recognition of his contribution to the industry in Australia and internationally,” Dr Cross said.
“While Medicines Australia will be sad to see him go, I have every confidence he will make a great contribution to the global pharmaceutical industry.
“His appointment is also a credit to the Australian pharmaceutical industry, being recognition of the high standing of Medicines Australia and the Australian industry internationally.
“We congratulate Brendan, wish him well and look forward to working with him in his new role at the IFPMA.”
Dr Cross also confirmed that Egon Zehnder had been appointed to work with the Medicines Australia Board in the search for a new Chief Executive.
“This is an important time for the industry in Australia and the Medicines Australia Board is keen to identify a strong candidate to take over the role from Brendan,” Dr Cross said.
“We have commenced a search process with Egon Zehnder and look forward to announcing Medicines Australia’s new Chief Executive in due course.”
Phone: (02) 6122 8503